Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder CancerNicola Annels, Hardev Pandha|Clinical Cancer Research|2019Cited by 120